EU Court Adviser on Vaccine Secrecy
Analysis based on 7 articles · First reported Jun 11, 2026 · Last updated Jun 12, 2026
The ongoing legal scrutiny and public debate over the International — European Commission's secret vaccine deals, particularly with Pfizer, could lead to increased regulatory pressure on pharmaceutical companies regarding transparency in government contracts. This event also highlights potential governance risks within the European Union, which may affect investor confidence in the stability and integrity of its institutions.
An adviser to the European Union — Court of Justice of the European Union, Athanasios Rantos, has issued an opinion stating that the International — European Commission was wrong to keep details of its Covid-19 vaccine contracts secret. This opinion is not legally binding but will inform the court's final ruling on the matter. The controversy, dubbed 'Pfizergate,' centers on Ursula von der Leyen's text message negotiations with Pfizer CEO Albert Bourla for a €35 billion vaccine deal and the International — European Commission's subsequent redaction of contract details and claims of lost messages. The International — European Commission had signed six advance purchase agreements with pharmaceutical companies, including Pfizer, AstraZeneca, and Moderna, worth a combined €71 billion. The International — European Commission lost a previous legal battle in 2024 to keep these details secret and appealed the decision. Ursula von der Leyen also survived a no-confidence vote in the European Union — European Parliament over the scandal.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard